- Quantum-SI Incorporated has agreed to merge with HighCape Capital Acquisition Corp. (Nasdaq: CAPA), a healthcare-focused special purpose acquisition company (SPAC) sponsored by HighCape Capital LP
- The transaction values Quantum-SI at approximately $1.46 billion and is expected to generate up to $514 million in gross proceeds
- The business combination is expected to close in the second quarter of 2021, and the combined company’s Class A common stock will trade on Nasdaq under the symbol “QSI”
Quantum-SI Incorporated, founded in 2013 by scientist and entrepreneur Dr. Jonathan Rothberg, developed a revolutionary semiconductor chip to sequence proteins, which has the potential to transform the burgeoning field of proteomics — the study of large-scale proteins. By digitizing proteomic research, Quantum-SI’s platform can potentially scale drug discovery involving genomics and proteomics beyond systems that use DNA sequencing and enable new diagnostic applications.
The company’s proposed business combination with HighCape Capital Acquisition Corp. (Nasdaq: CAPA), a healthcare-focused special purpose acquisition company (SPAC) sponsored by growth equity investment firm HighCape Capital LP, will facilitate Quantum-SI’s plan to launch its platform commercially in 2022 for research use.
Mintz is acting as legal advisor to Quantum-SI in its proposed merger with HighCape Capital Acquisition Corp., a transaction valued at $1.46 billion with expected proceeds of $514 million. Michael Fantozzi, Chair of the firm’s Corporate, Tax, Private Client & Immigration Division, is leading Mintz team’s work on the transaction with assistance from Ran Zioni, Chair of Mintz’s Israel Practice, and Member and corporate attorney John Condon.
The transaction is expected to be completed by the second quarter of 2021, after which the combined company’s Class A common stock will trade under the symbol “QSI” on the Nasdaq exchange. The Mintz team is looking forward to continuing to advise Quantum-SI.